Day One Biopharmaceuticals upsizes IPO to 10 million shares from 8.4 million

Day One Biopharmaceuticals Inc. DAWN, which specializes in developing cancer treatments for children, increased its IPO on Wednesday to 10 million shares of an earlier plan to offer 8.4 million. The company is still proposing a price range of $ 14 to $ 16 per share. Day One said it expects a return of about $ 135.5 million in the middle of that range, or about $ 156.4 million if the underwriters exercise an option to buy an additional 1.5 million shares. The company has signed up for the listing on Nasdaq, under the ticker “DAWN.” JPMorgan, Cowen, Piper Sandler and Wedbush PacGrow endorse the deal. The proceeds will be used to fund clinical trials and for working capital and general corporate purposes. “Day One was created to address a critical unmet need: children with cancer are left behind in a revolution in cancer drug development,” the company said in its prospectus. . “Our name is inspired by” The Day One Talk “that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. We strive to rethink the development of cancer drugs and redefine what is possible for all. people with cancer regardless of age from day one. “

Comments are closed.